Triptorelin (Decapeptyl SR) for premenopausal women with early endocrine responsive breast cancer

NIHR HSRIC

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age and have already gone through the menopause. However, younger women, and in rare cases, men, may also get breast cancer. There are many types of breast cancer. Triptorelin is a new treatment for a type of early breast cancer that usually occurs in younger women who have not gone through the menopause, and is described as hormone receptor-positive. Triptorelin is given as an injection straight into a muscle every 28 days along with hormonal therapy tablets that are already widely used for breast cancer. Studies at the moment are aiming to show how well these treatments work together and that triptorelin is safe to use. If triptorelin is licenced for use in the UK, it will provide a new treatment option for this patient group.

Final publication URL
http://www.hsric.nihr.ac.uk/topics/triptorelin-decapeptyl-sr-for-premenopausal-women-with-early-endocrine-responsive-breast-cancer/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Breast; Breast Neoplasms; Endocrine Gland Neoplasms; Female; Premenopause; Triptorelin Pamoate

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

AccessionNumber
32016000437

Date abstract record published
04/03/2016